Doxorubicin HCl

Doxorubicin HCl — Doxorubicin HCl supplied by MOLEQULE-ON, New Zealand; Supplier: EMDA. This listing refers to a 20 mg presentation (see Size: 20mg) of the anthracycline antitumor antibiotic commonly used in systemic oncology regimens.

Overview: Doxorubicin hydrochloride is an anthracycline topoisomerase II inhibitor that intercalates DNA and induces free-radical damage, used as a cytotoxic agent in multi-agent and single-agent chemotherapy for a broad range of malignancies (breast, lymphomas, leukemias, sarcomas and others). (pfizermedical.com)

• Active ingredient: Doxorubicin hydrochloride (anthracycline).
• Strength / presentation: 20 mg vial (single-use oncology presentation).
• Dosage form & route: Injectable for intravenous use (powder for reconstitution or solution depending on supplier batch); administration must be performed by qualified healthcare professionals. (ncbi.nlm.nih.gov)
• Key clinical features: Broad antitumor activity; commonly used in adjuvant and metastatic settings as part of established regimens. (pfizermedical.com)
• Warnings & precautions: Cytotoxic and vesicant — risk of severe local tissue necrosis on extravasation; dose-related cardiotoxicity (lifetime cumulative dose limits and cardiac monitoring recommended); severe myelosuppression and secondary malignancy risk. Use appropriate PPE and hazardous-drug handling procedures. (onf.ons.org)
• Storage & handling: Store refrigerated (commonly 2-8°C) and protect from light; follow institutional safe handling and disposal policies for hazardous antineoplastic agents. (medthority.com)

Clinical use and administration details (dosing regimens, hepatic adjustment, monitoring and contraindications) vary by indication and patient factors; only licensed prescribers and trained oncology pharmacists/nurses should select and prepare this product. (pfizermedical.com)